Key Decisions Approved
1. Unaudited Financial Results: Approval of standalone and consolidated financial results for quarter ended June 30, 2026, pursuant to Regulation 33 of SEBI Listing Regulations.
2. Subsidiary Incorporation: Approval for incorporation of 'PI Foundation' as a Wholly Owned Subsidiary under Section 8 of Companies Act, 2013 for CSR activities.
Financial Results - Standalone (₹ Million)
Quarter Ended June 30, 2026 (Q1 FY27) vs Comparative Periods:
- Revenue from operations: ₹15,989 (Q1 FY26: ₹17,691; Q4 FY26: ₹13,914)
- Other income: ₹608 (Q1 FY26: ₹800; Q4 FY26: ₹711)
- Total income: ₹16,597 (Q1 FY26: ₹18,491; Q4 FY26: ₹14,625)
- Profit before exceptional items and tax: ₹4,370 (Q1 FY26: ₹5,815; Q4 FY26: ₹3,696)
- Exceptional items: Nil (Q4 FY26: loss of ₹1,117)
- Profit after tax: ₹3,415 (Q1 FY26: ₹4,643; Q4 FY26: ₹1,978)
- Basic EPS: ₹22.50 (Q1 FY26: ₹30.61; Q4 FY26: ₹13.04)
- Diluted EPS: ₹22.50 (Q1 FY26: ₹30.60; Q4 FY26: ₹13.03)
Expense Breakdown (Q1 FY27):
- Cost of materials consumed: ₹6,285
- Employee benefit expense: ₹1,754
- Depreciation and amortization: ₹803
- Other expense: ₹2,591
- Total expenses: ₹12,227
Financial Results - Consolidated (₹ Million)
Quarter Ended June 30, 2026 (Q1 FY27) vs Comparative Periods:
- Revenue from operations: ₹17,023 (Q1 FY26: ₹19,005; Q4 FY26: ₹15,652)
- Other income: ₹641 (Q1 FY26: ₹859; Q4 FY26: ₹756)
- Total income: ₹17,664 (Q1 FY26: ₹19,864; Q4 FY26: ₹16,408)
- Profit before exceptional items and tax: ₹3,218 (Q1 FY26: ₹5,074; Q4 FY26: ₹3,025)
- Exceptional items: Nil (Q4 FY26: loss of ₹20)
- Profit after tax: ₹2,442 (Q1 FY26: ₹4,000; Q4 FY26: ₹2,002)
- Basic EPS: ₹16.10 (Q1 FY26: ₹26.37; Q4 FY26: ₹13.20)
- Diluted EPS: ₹16.10 (Q1 FY26: ₹26.36; Q4 FY26: ₹13.20)
Segment Performance (Consolidated, Q1 FY27)
- Agro chemicals segment profit before tax: ₹3,835 million
- Pharma segment loss before tax: ₹(816) million
- Inter-segment adjustment: ₹199 million
Exceptional Items Explanation
Standalone (Previous Quarter):
1. Provision of ₹1,100 million recognized in Q4 FY26 for equity investment in PIHS due to business losses based on independent valuer's assessment.
2. Incremental liability of ₹223 million in Q4 FY26 due to reassessment of employee benefit obligations under New Labour Codes notified November 2025.
Consolidated (Previous Year):
1. Write-back of contingent consideration of ₹1,260 million in FY26 due to renegotiated settlement with erstwhile owners of acquired businesses.
2. Incremental liability of ₹229 million in FY26 due to reassessment of employee benefit obligations under New Labour Codes.
Subsidiary Formation Details
- Name: PI Foundation (or other approved name)
- Type: Section 8 company (not-for-profit)
- Purpose: Corporate Social Responsibility activities under Section 135 read with Schedule VII of Companies Act
- Ownership: 100% wholly owned subsidiary (direct or indirect) of PI Industries Limited
- Initial capital subscription: ₹100,000 in cash
- Approval required: Registrar of Companies, Jaipur, Ministry of Corporate Affairs
Board Meeting Details
- Date: August 11, 2026
- Time: 2:00 PM to 6:30 PM IST
- Location: Not specified in document
Auditor Review
Price Waterhouse Chartered Accountants LLP conducted limited review of both standalone and consolidated financial results and issued unmodified conclusion that the statements are free from material misstatement and prepared in accordance with applicable accounting standards and SEBI regulations.
Consolidated Entity Structure
The consolidated results include:
- Parent: PI Industries Limited
- 18 subsidiaries including PI Health Sciences Limited, Archimica S.p.A, various PI AgSciences entities
- Controlled trust: PI ESOP Trust
- Joint venture: PI Kumiai Private Limited
- Associate: Solinnos Agro Sciences Private Limited
Capital Structure
- Paid-up equity share capital: ₹152 million (face value ₹1 each)
- Other equity (standalone): ₹113,539 million as per balance sheet
- Other equity (consolidated): ₹112,153 million as per balance sheet